Corcept Therapeutics (CORT) Expected to Announce Quarterly Earnings on Wednesday

Corcept Therapeutics (NASDAQ:CORT) is projected to post its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect Corcept Therapeutics to post earnings of $0.27 per share for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 5:00 PM ET.

Corcept Therapeutics Trading Down 0.9%

Shares of Corcept Therapeutics stock opened at $39.63 on Wednesday. The company has a current ratio of 3.14, a quick ratio of 3.07 and a debt-to-equity ratio of 0.01. The company has a fifty day simple moving average of $52.17 and a 200-day simple moving average of $67.68. The stock has a market cap of $4.17 billion, a price-to-earnings ratio of 45.03 and a beta of 0.25. Corcept Therapeutics has a 12-month low of $32.99 and a 12-month high of $117.33.

Analyst Ratings Changes

Several equities analysts have issued reports on CORT shares. Wolfe Research cut Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 target price on the stock. in a research report on Wednesday, December 31st. UBS Group started coverage on Corcept Therapeutics in a research note on Tuesday, December 16th. They issued a “neutral” rating and a $95.00 price target on the stock. Weiss Ratings reissued a “hold (c)” rating on shares of Corcept Therapeutics in a report on Monday, December 29th. Canaccord Genuity Group boosted their price target on shares of Corcept Therapeutics from $99.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, January 23rd. Finally, HC Wainwright upped their price target on Corcept Therapeutics from $90.00 to $105.00 and gave the company a “buy” rating in a research report on Thursday, January 22nd. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $83.50.

Insider Buying and Selling at Corcept Therapeutics

In other Corcept Therapeutics news, insider Joseph Douglas Lyon sold 5,000 shares of the stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $79.53, for a total transaction of $397,650.00. Following the completion of the transaction, the insider owned 10,277 shares in the company, valued at approximately $817,329.81. This represents a 32.73% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Sean Maduck sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $79.52, for a total value of $1,590,400.00. Following the completion of the sale, the insider owned 7,904 shares in the company, valued at $628,526.08. The trade was a 71.67% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 129,500 shares of company stock valued at $8,665,500. 20.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Corcept Therapeutics

A number of institutional investors have recently added to or reduced their stakes in CORT. Advisory Services Network LLC acquired a new stake in Corcept Therapeutics during the 3rd quarter valued at approximately $25,000. Larson Financial Group LLC boosted its position in Corcept Therapeutics by 2,326.3% during the third quarter. Larson Financial Group LLC now owns 461 shares of the biotechnology company’s stock valued at $38,000 after acquiring an additional 442 shares during the last quarter. Gould Capital LLC grew its holdings in Corcept Therapeutics by 50.0% during the 3rd quarter. Gould Capital LLC now owns 600 shares of the biotechnology company’s stock worth $50,000 after acquiring an additional 200 shares during the period. CIBC Private Wealth Group LLC grew its stake in Corcept Therapeutics by 128.5% during the third quarter. CIBC Private Wealth Group LLC now owns 770 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 433 shares during the period. Finally, Harvest Fund Management Co. Ltd acquired a new position in Corcept Therapeutics in the third quarter valued at approximately $69,000. 93.61% of the stock is currently owned by institutional investors and hedge funds.

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.